Non-Current Liabilities
Operating Lease Liabilities (Total)
Neurocrine Biosciences Operating Lease Liabilities (Total) decreased by 1.7% to $463.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 6.0%, from $493.10M to $463.50M. Over 5 years (FY 2020 to FY 2025), Operating Lease Liabilities (Total) shows an upward trend with a 35.1% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Liabilities
CategoryLeverage
SignalContext dependent
VolatilityModerate
First reportedQ1 2019
Last reportedQ1 2026May 5, 2026
How to read this metric
An increase indicates expansion of the leased asset base, while a decrease suggests a reduction in lease commitments or the expiration of lease terms.
Detailed definition
This represents the total present value of future lease payments for operating leases, recognized as a liability on the...
Peer comparison
Standardized under modern accounting rules, allowing for direct comparison of lease-based financing across companies in the same sector.
Metric ID:
operating_lease_liabilities_totalHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $124.00M | $121.90M | $121.80M | $119.40M | $116.70M | $113.90M | $110.90M | $108.00M | $106.80M | $103.70M | $290.30M | $287.90M | $291.60M | $286.20M | $495.70M | $493.10M | $489.80M | $479.70M | $471.30M | $463.50M |
| QoQ Change | — | -1.7% | -0.1% | -2.0% | -2.3% | -2.4% | -2.6% | -2.6% | -1.1% | -2.9% | +179.9% | -0.8% | +1.3% | -1.9% | +73.2% | -0.5% | -0.7% | -2.1% | -1.8% | -1.7% |
| YoY Change | — | — | — | — | -5.9% | -6.6% | -8.9% | -9.5% | -8.5% | -9.0% | +161.8% | +166.6% | +173.0% | +176.0% | +70.8% | +71.3% | +68.0% | +67.6% | -4.9% | -6.0% |
Range$103.70M – $495.70M
CAGR+32.0%
Avg YoY Growth+56.0%
Median YoY Growth+31.3%
Current Streak5 quarters decline
Operating Lease Liabilities (Total) at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's operating lease liabilities (total)?
- Neurocrine Biosciences (NBIX) reported operating lease liabilities (total) of $463.50M in Q1 2026.
- How has Neurocrine Biosciences's operating lease liabilities (total) changed year-over-year?
- Neurocrine Biosciences's operating lease liabilities (total) decreased by 6.0% year-over-year, from $493.10M to $463.50M.
- What is the long-term trend for Neurocrine Biosciences's operating lease liabilities (total)?
- Over 5 years (2020 to 2025), Neurocrine Biosciences's operating lease liabilities (total) has grown at a 35.1% compound annual growth rate (CAGR), from $104.70M to $471.30M.
- What does operating lease liabilities (total) mean?
- The total value of future payments the company is obligated to make for leased assets.